Page 625 - Read Online

Page 10 of 11 Ichida et al. Hepatoma Res 2020;6:54 I http://dx.doi.org/10.20517/2394-5079.2020.59

Financial support and sponsorship
None.

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
The current study was approved as project number 2158-(6) by Graduate School of Medicine and Faculty
of Medicine, the University of Tokyo Research Ethics Committee/Institutional Review Board. Informed
consent was obtained in the form of opt-out on the web-site (http://www.u-tokyo-hbp-transplant-surgery.
jp/).

Consent for publication
Not applicable.

Copyright
© The Author(s) 2020.

REFERENCES
1. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, et al. Liver transplantation for the treatment of small hepatocellular
carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-9.
2. Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, et al. Liver transplantation for hepa tocellular carcinoma: expansion of the tumor size
limits does not adversely impact survival. Hepatology 2001;33:1394-403.
3. Sugawara Y, Tamura S, Makuuchi M. Living donor liver transplantation for hepatocellular carcinoma: Tokyo University series. Dig Dis
2007;25:310-12.
4. Lee SG, Hwang S, Moon DB, Ahn CS, Kim KH, et al. Expanded indication criteria of living donor liver transplantation for hepatocellular
carcinoma at one large-volume center. Liver Transpl 2008;14:935-45.
5. Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, et al. Predicting survival after liver transplantation in patients with
hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009;10:35-43.
6. Ito T, Takada Y, Ueda M, Haga H, Maetani Y, et al. Expansion of selection criteria for patients with hepatocellular carcinoma in living
donor liver transplantation. Liver Transpl 2007;13:1637-44.
7. Toso C, Asthana S, Bigam DL, Shapiro AM, Kneteman NM. Reassessing selection criteria prior to liver transplantation for hepatocellular
carcinoma utilizing the scientific registry of transplant recipients database. Hepatology 2008;49:832-8.
8. Taketomi A, Sanefuji K, Soejima Y, Yoshizumi T, Uchiyama H, et al. Impact of des-gamma-carboxy prothrombin and tumor size on the
recurrence of hepatocellular carcinoma after living donor liver transplantation. Transplantation 2009;87:531-7.
9. DuBay D, Sandroussi C, Sandhu L, Cleary S, Guba M, et al. Liver transplantation for advanced hepatocellular carcinoma using poor
tumor differentiation on biopsy as an exclusion criterion. Ann Surg 2011;253:166-72.
10. Kim JM, Kwon CH, Joh JW, Park JB, Lee JH, et al. Expanded criteria for liver transplantation in patients with hepatocellular carcinoma.
Trans plant Proc 2014;46:726-9.
11. Llovet JM. Expanding HCC criteria for liver transplant: the urgent need for prospective, robust data. Liver Transpl 2006;12:1741-3.
12. Duvoux C, Roudot Thoraval F, Decaens T, Pessione F, et al. Liver transplantation for hepatocellular carcinoma: a model including
α-fetoprotein improves the performance of Milan criteria. Gastroenterology 2012;143:986-94.
13. Mehta N, Heimbach J, Harnois DM, Sapisochin G, Dodge JL, et al. Validation of a risk estimation of tumor recurrence after transplant
(RETREAT) score for hepatocellular carcinoma recurrence after liver transplant. JAMA Oncol 2017;3:493-500.
14. Lai Q, Nicolini D, Inostroza Nunez M, Iesari S, Goffette P, et al. A novel prognostic index in patients with hepatocellular cancer waiting
for liver transplantation: Time-Radiological-response-Alpha-fetoprotein-INflammation (TRAIN) score. Ann Surg 2016;264:787-96.
15. Lee JH, Cho Y, Kim HY, Cho EJ, Lee DH, et al. Serum tumor markers provide refined prognostication in selecting liver transplantation
candidate for hepatocellular carcinoma patients beyond the Milan criteria. Ann Surg 2016;263:842-50.
16. Halazun KJ, Hardy MA, Rana AA, Woodland DC 4th, Luyten EJ, et al. Negative impact of neutrophil-lymphocyte ratio on outcome after
liver transplantation for hepatocellular carcinoma. Ann Surg 2009;250:141-51.
17. Zheng J, Cai J, Li H, Zeng K, He L, et al. Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio as prognostic predictors for
hepatocellular carcinoma patients with various treatments: a meta-analysis and systematic review. Cell Physiol Biochem 2017;44:967-81.
18. Hong G, Suh KS, Suh SW, Yoo T, Kim H, et al. Alpha-fetoprotein and (18)F-FDG positron emission tomography predict tumor
recurrence better than Milan criteria in living donor liver transplantation. J Hepatol 2016;64:852-9.
19. Takada Y, Kaido T, Shirabe K, Nagano H, Egawa H, et al. Significance of preoperative fluorodeoxyglucose-positron emission tomography
in prediction of tumor recurrence after liver transplantation for hepatocellular carcinoma patients: a Japanese multicenter study. J